Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Post by Gamestorm7on Oct 04, 2018 10:50am
110 Views
Post# 28744400

Standing Ground

Standing GroundI am with you ForexWhale.  My exit strategy is set for around $1.  I am willing to wait for that day to come and have done my DD which suggests it will.  Yes it is frustrating waiting for funding news; but at the same time, all good deals take time.

Personally, I don't forsee the company doing a PP at the current stock price or lower.  If a PP is initiated, I believe Andrew will release news and information which will drive the stock higher before any PP is announced.  In view of the positive Phase 1 results, full data analysis on it's way and potential material payment from IMNP in the next three months I believe iCo is setup to obtain funding without a PP.  Depending how long you have been invested in iCo or how much DD you have done, one knows the company has been in talks with various Pharma companies discussing possible partnership or JV deals for Oral Amp B in an attempt to provide shareholders value and avoid major dillution in past years.  With such positive Phase I results, I believe iCo will obtain a partner or JV deal to fund Oral Amp B through Phase II and Phase III.  Any prospective partner or JV participant was likely wanting Phase I complete before stepping up to the plate.

All of this, is my personal opinion.  I will be standing my ground here as well and will not be tricked into selling my shares by the manipulators.  Good luck everyone!
<< Previous
Bullboard Posts
Next >>